Combo Product Firms Want Simpler Adverse Event Reporting Structure
This article was originally published in The Gray Sheet
Executive Summary
FDA's proposed adverse event reporting requirements for combination products should be rewritten to simplify the way events are reported when multiple manufacturers are involved, firms say